Biosimilars

EPC HealthCare works with INSIGHT Health data. Combined with our previous experience with biosimilars and our long-standing contacts with health insurance companies, it enables us to develop a tailor-made strategy for the successful market entry of our clients' biosimilars.

Their great economic and pharma-political importance turns biosimilars into an exciting and, above all, promising market segment. However, the marketing of biosimilars in Germany is by no means a self-propelling process. Regional drug control at the level of the 17 health insurances is undergoing change and requires individual strategies for the 16 federal states with regard to the respective regional control mechanisms. For success in the market, knowledge of the federal treaties, quota regulations, lead substances, guideline values and volume targets is just as important as access to all relevant market data.